Botox Tested on Stomach Cancer in Mice
Preliminary research suggests the wrinkle treatment might silence critical nerves that support tumors
By Randy Dotinga
WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Botox, the wrinkle fighter, might be a cancer fighter, too, according to a new animal study.
Researchers working with mice are using Botox to try to combat stomach cancer by silencing nerves that connect to tumors. The work is still in its very early stages, and a prominent cancer expert cautioned that the approach is far from ready for prime time.
While the study findings are intriguing and worth pursing, "it would be inappropriate to pursue this treatment outside of a clinical trial," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "Remember that this is a mouse experiment. These types of experiments have been done for decades, and the actual translation into benefiting patients is uncommon."
Stomach cancer, also known as gastric cancer, will kill an estimated 11,000 people in the United States this year, according to the National Cancer Institute.
It creates special challenges for treatment because it's generally "silent," Lichtenfeld said, explaining stomach cancer doesn't become noticeable until it's so advanced that patents require extensive surgery or chemotherapy.
While not one of the most common cancers in the United States, rising rates of obesity and reflux disease have boosted certain types of stomach cancer, Lichtenfeld said. Rates of stomach cancer are much higher in Southeast Asia and Japan.
Scientists think nerves are crucial to tumor growth, but the role they play isn't clear. In the new study, published in the Aug. 20 issue of Science Translational Medicine, researchers try to silence the nerves that connect to the stomach and seem to support tumors.
In mice with a rough equivalent of human stomach cancer, the researchers tried several approaches, including cutting nerves to the stomach or paralyzing them with injections of Botox.
"The nerves are silenced or muted, unable to signal to the stem cells and cancer stem cells in the stomach," said study co-author Dr. Timothy Wang, professor of medicine and chief of digestive and liver diseases at Columbia University Medical Center in New York City.